BioCentury | Oct 20, 2015
Financial News

NantWorks invests $50M in Precision Biologics

...colorectal cancer. The chimeric mAb targeting a variant of musin 5AC oligomeric mucus/gel forming ( MUC5AC...
BioCentury | Jun 8, 2015
Clinical News

Ensituximab: Completed Phase II enrollment

...NPC-1C ) Business: Cancer Molecular target: Mucin 5AC oligomeric mucus/gel-forming (MUC5AC) Description: Chimeric mAb targeting a variant of mucin 5AC oligomeric mucus/gel-forming (MUC5AC)...
BioCentury | Apr 28, 2014
Clinical News

NEO-102: Interim Phase I/IIa data

...Texas Product: NEO-102 Business: Cancer Molecular target: Mucin 5AC oligomeric mucus/gel-forming (MUC5AC) Description: Chimeric mAb targeting a variant of mucin 5AC oligomeric mucus/gel-forming (MUC5AC)...
BioCentury | Jun 10, 2013
Clinical News

Ensituximab: Phase I/IIa data

...NEO-101 ) Business: Cancer Molecular target: Mucin 5AC oligomeric mucus/gel-forming (MUC5AC) Description: Chimeric mAb targeting a variant of mucin 5AC oligomeric mucus/gel-forming (MUC5AC)...
BioCentury | Apr 22, 2013
Clinical News

Ensituximab: Phase I data

...NEO-101 ) Business: Cancer Molecular target: Mucin 5AC oligomeric mucus/gel-forming (MUC5AC) Description: Chimeric mAb targeting a variant of mucin 5AC oligomeric mucus/gel-forming (MUC5AC)...
BioCentury | Oct 4, 2012
Distillery Therapeutics

Indication: Infectious disease

...MUC5AC levels in the lungs could help protect against influenza infection. In transgenic mice overexpressing Muc5ac...
Items per page:
1 - 6 of 6